Healthy Outlook for Healthcare Supported by Trial Milestones, Approvals, Partnerships, and Commercialization - Research Report on Lilly, Celgene, Onyx, Amgen, and GSK

NEW YORK, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Eli Lilly and Company (NYSE: LLY), Celgene Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Amgen Inc. (NASDAQ: AMGN), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Eli Lilly and Company Research Report

On August 13, 2013, Eli Lilly and Company (Lilly) announced that the recently completed Phase III study, SQUIRE, has successfully reached the Company's primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC) witnessed increased overall survival (OS) when administered necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line treatment, as compared to chemotherapy alone. Richard Gaynor, M.D., Vice President of Product Development and Medical Affairs for Lilly Oncology, commented, "We are pleased with these data which represent a potential advance in treatment for patients with squamous non-small cell lung cancer, which is a difficult cancer to treat. If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer." The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

Celgene Corporation Research Report  

On August 9, 2013, Celgene Corporation's (Celgene) wholly-owned subsidiary, Celgene International Sàrl announced that it has received an approval from the European Commission (EC) for Pomalidomide in combination with dexamethasone, for the treatment of relapsed and refractory multiple myeloma (rrMM). According to Celgene, Oral Anti-Cancer Therapy, Pomalidomide is expected to treat the rare form of blood cancer in adult patients who have received at least two prior therapies including both lenalidomide and bortezomib and have demonstrated disease progression on the last therapy. After submission of a regulatory notification to the European Medicines Agency (EMA) to change the trade name, the Company intends to launch Pomalidomide Celgene in the European Union under the trade name "IMNOVID". Dr. Xavier Leleu, Hôpital Huriez, CHRU Lille, France, said, "Most patients diagnosed with multiple myeloma will relapse at some point and I have seen many patients who have become refractory to a number of treatments. The urgency now is to develop novel agents that help those patients who have tried several therapies and exhausted current standards of care. The approval of pomalidomide, one of these novel agents, is great news and a major step forward for these patients across Europe who need a new effective treatment option to help manage their disease." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/7f47_CELG]

Onyx Pharmaceuticals, Inc. Research Report

On August 8, 2013, Onyx Pharmaceuticals, Inc. (Onyx) announced its partnership with Idis Limited for the initiation of the Managed Access Program for carfilzomib in certain European countries. Onyx reported that carfilzomib is likely to treat patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and their disease have progressed on or within 60 days of completion of the last therapy. Tony Dutta, Managing Director of Idis, stated, "Through our work with Onyx Pharmaceuticals, we will share our expertise in successfully addressing access challenges and help educate a broad range of stakeholders on navigating the options and obstacles that exist for these patients." The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fcf2_ONXX]

Amgen Inc. Research Report

On August 12, 2013, Amgen Inc. (Amgen) and Servier announced that the completion of  the cardiovascular product collaboration agreement between the duos, reported on July 8, 2013, after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Amgen reported according to the agreement, the Company has secured US commercial rights for Servier's novel oral drug, approved in the EU as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with increased heart rates. The Company also stated that it has received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. Amgen further informed that, under the collaboration agreement, Servier will have an exclusive option to commercialize omecamtiv mecarbil in Europe. The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e96b_AMGN]

GlaxoSmithKline plc Research Report

On August 12, 2013, GlaxoSmithKline plc's (GSK) joint venture with Pfizer, ViiV Healthcare announced that it has received an approval for Tivicay (dolutegravir) 50-mg tablets from the US Food and Drug Administration (FDA). Dr. Dominique Limet, CEO of ViiV Healthcare, said, "Today is a very important milestone for patients and the scientists and teams who developed Tivicay and brought it to this point of FDA approval. I am very proud that we are serving people living with HIV with a much-needed new treatment option. Today's approval shows that our singular focus on HIV can deliver important new medicines, maintaining our absolute commitment to the HIV/AIDS global response." According to GSK, Tivicay is an integrase inhibitor to be used in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner